TNSN07141A1 - Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms - Google Patents

Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Info

Publication number
TNSN07141A1
TNSN07141A1 TNP2007000141A TNSN07141A TNSN07141A1 TN SN07141 A1 TNSN07141 A1 TN SN07141A1 TN P2007000141 A TNP2007000141 A TN P2007000141A TN SN07141 A TNSN07141 A TN SN07141A TN SN07141 A1 TNSN07141 A1 TN SN07141A1
Authority
TN
Tunisia
Prior art keywords
methylpiperazin
ylamino
benzamide
pyrimidin
ylmethyl
Prior art date
Application number
TNP2007000141A
Other languages
English (en)
French (fr)
Inventor
Andrea Louis Dewar
Timothy Peter Hughes
Alan Bruce Lyons
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of TNSN07141A1 publication Critical patent/TNSN07141A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2007000141A 2004-10-18 2007-04-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms TNSN07141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18
PCT/AU2005/001602 WO2006042362A1 (en) 2004-10-18 2005-10-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Publications (1)

Publication Number Publication Date
TNSN07141A1 true TNSN07141A1 (en) 2008-11-21

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000141A TNSN07141A1 (en) 2004-10-18 2007-04-17 Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms

Country Status (19)

Country Link
US (1) US20080255139A1 (https=)
EP (1) EP1804800B1 (https=)
JP (1) JP2008516898A (https=)
KR (1) KR20070083705A (https=)
CN (1) CN101035535A (https=)
AT (1) ATE492277T1 (https=)
AU (1) AU2005297321A1 (https=)
BR (1) BRPI0517083A (https=)
CA (1) CA2580976A1 (https=)
DE (1) DE602005025514D1 (https=)
IL (1) IL182419A0 (https=)
MA (1) MA28946B1 (https=)
MX (1) MX2007004660A (https=)
NO (1) NO20072501L (https=)
NZ (1) NZ554009A (https=)
RU (1) RU2007118420A (https=)
TN (1) TNSN07141A1 (https=)
WO (1) WO2006042362A1 (https=)
ZA (1) ZA200702316B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058968A2 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
CN107530430A (zh) * 2015-01-13 2018-01-02 国立大学法人京都大学 用于预防和/或治疗肌萎缩性侧索硬化症的药剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt

Also Published As

Publication number Publication date
AU2005297321A1 (en) 2006-04-27
MA28946B1 (fr) 2007-10-01
DE602005025514D1 (de) 2011-02-03
NO20072501L (no) 2007-05-15
KR20070083705A (ko) 2007-08-24
NZ554009A (en) 2010-09-30
JP2008516898A (ja) 2008-05-22
IL182419A0 (en) 2007-09-20
EP1804800B1 (en) 2010-12-22
ZA200702316B (en) 2008-09-25
WO2006042362A1 (en) 2006-04-27
CA2580976A1 (en) 2006-04-27
EP1804800A4 (en) 2008-03-19
BRPI0517083A (pt) 2008-09-30
ATE492277T1 (de) 2011-01-15
EP1804800A1 (en) 2007-07-11
RU2007118420A (ru) 2008-11-27
CN101035535A (zh) 2007-09-12
MX2007004660A (es) 2007-10-17
US20080255139A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
MY159522A (en) Administration of dipeptidyl peptidase inhibitors
MX2022000826A (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
PH12016500243A1 (en) Sustained release dosage forms for a jak1 inhibitor
CO6450624A2 (es) Compuestos vinil indazolilo
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
HUE034712T2 (hu) Amidszármazék és gyógyszer
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
MY146403A (en) F, g, h, i and k crystal forms of imatinib mesylate
PE20141337A1 (es) Formulacion de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida
TNSN07141A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti